ALLOY UTI Vaccine

About Syntiron

Syntiron is a private, preclinical-stage biotech company dedicated to developing bacterial vaccines to address the global crisis of antimicrobial resistance (AMR). Its proprietary ALLOY Vaccine Platform generates synthetic protein vaccines that target multiple bacterial iron receptors, aiming for strength, broad protection, and manufacturing simplicity. The company's lead program is a vaccine for urinary tract infections (UTI), a major driver of antibiotic use, and it has secured non-dilutive funding from CARB-X for a maternal vaccine to prevent neonatal sepsis. Syntiron operates as a small, focused team leveraging deep expertise in microbial genomics and structural biochemistry to advance its pipeline.

Therapeutic Areas